Pharmathen's new Research and Development Centre in Pallini, Athens

Pharmathen S.A announced the establishment of a new Research and Development Centre in Pallini, Athens. The new Research Centre will focus on developing Generic molecules and is expected to significantly reinforce Pharmathen's already excellent R&D capabilities. Pharmathen is one of the strongest generic developer in Europe and with the operation of the new facility the company's R&D activities will be further increased. The new state-of-the-art centre is equipped with the most technologically advanced instruments and laboratory machinery. Furthermore the new R&D centre will initially employ 70 scientists with advanced academic qualifications and long-term experience in research.

The establishment of the new research centre is the latest addition in a series of investments which have taken place over the last three years including the API R&D centre in Thessaloniki; the Innovative Formulation Laboratory also in Thessaloniki; the new manufacturing plant in Pikermi, Athens; and the new manufacturing plant in Sapes, Northern Greece, which is currently under construction and it is expected to be operational by the end of 2008. The new R&D centre will be in close cooperation with the other research units of Pharmathen.

Pharmathen is already a fully integrated company from API to finished formulations and the new facility will reinforce further its integration, allowing the company to provide a fully backwardly integrated quality service to its clients worldwide.

About Pharmathen Pharmaceuticals
Located in Athens, Greece, Pharmathen Pharmaceuticals is a private pharmaceutical company focused on developing and marketing of health care products, with a strong position in generics. Founded in 1969 by Dr. Nicolas Katsos, it is one of the fastest growing pharmaceutical companies in Greece.

With a long history of development and manufacturing of generic products, Pharmathen has emerged as one of the largest generic development companies in Europe with a development pipeline of ten generic molecules a year.

For further information, please visit www.pharmathen.gr.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...